USA - NASDAQ:CTMX - US23284F1057 - Common Stock
Taking everything into account, CTMX scores 5 out of 10 in our fundamental rating. CTMX was compared to 536 industry peers in the Biotechnology industry. While CTMX has a great health rating, its profitability is only average at the moment. CTMX is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 27.41% | ||
ROE | 40.02% | ||
ROIC | 25.08% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 30.56% | ||
PM (TTM) | 34.01% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 3.02 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.2 | ||
Quick Ratio | 4.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 5.61 | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 6.12 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
3.2
-0.08 (-2.44%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 5.61 | ||
Fwd PE | N/A | ||
P/S | 3.74 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.4 | ||
P/tB | 4.46 | ||
EV/EBITDA | 6.12 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 27.41% | ||
ROE | 40.02% | ||
ROCE | 31.75% | ||
ROIC | 25.08% | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | 30.56% | ||
PM (TTM) | 34.01% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 15.57% | ||
Cap/Sales | 0.17% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.2 | ||
Quick Ratio | 4.2 | ||
Altman-Z | 3.02 |